Related references
Note: Only part of the references are listed.Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies
Wenyan Fu et al.
MABS (2014)
Estrogen regulation of Dkk1 and Wnt/β-Catenin signaling in neurodegenerative disease
Erin L. Scott et al.
BRAIN RESEARCH (2013)
Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View
Shi Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Sox Transcription Factors Require Selective Interactions with Oct4 and Specific Transactivation Functions to Mediate Reprogramming
Irene Aksoy et al.
STEM CELLS (2013)
Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients
Claudio Coco et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Mapping of DNA Sex-Specific Markers and Genes Related to Sex Differentiation in Turbot (Scophthalmus maximus)
Ana Vinas et al.
MARINE BIOTECHNOLOGY (2012)
Deciphering the Sox-Oct partner code by quantitative cooperativity measurements
Calista K. L. Ng et al.
NUCLEIC ACIDS RESEARCH (2012)
Molecular Targeted Therapies in Hepatocellular Carcinoma
Shinji Tanaka et al.
SEMINARS IN ONCOLOGY (2012)
Sox2 Activates Cell Proliferation and Differentiation in the Respiratory Epithelium
David H. Tompkins et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
SOX2 Is an Oncogene Activated by Recurrent 3q26.3 Amplifications in Human Lung Squamous Cell Carcinomas
Thomas Hussenet et al.
PLOS ONE (2010)
Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung
Ping Yuan et al.
PLOS ONE (2010)
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
Adam J. Bass et al.
NATURE GENETICS (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Sox2 Is Required for Maintenance and Differentiation of Bronchiolar Clara, Ciliated, and Goblet Cells
David H. Tompkins et al.
PLOS ONE (2009)
Epigenetic inactivation of the canonical Wnt antagonist SRY-Box containing gene 17 in colorectal cancer
Wei Zhang et al.
CANCER RESEARCH (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models
Kaori Fujimoto-Ouchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Nucleus- and cell-specific gene expression in monkey thalamus
Karl D. Murray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Development of Herceptin resistance in breast cancer cells
T Kute et al.
CYTOMETRY PART A (2004)
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
YM Li et al.
CANCER CELL (2004)
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
C Knuefermann et al.
ONCOGENE (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Expression of the LIM-homeodomain gene Lmx1a (dreher) during development of the mouse nervous system
V Failli et al.
MECHANISMS OF DEVELOPMENT (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Rat MUC4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistance
SA Price-Schiavi et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Breast cancer in the 21st century: Neu opportunities and neu challenges
SJ Schnitt
MODERN PATHOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
